RxDoctor Payments Data

Lorenzo Ottaviano, MD

Gastroenterology · New York, NYNPI 1225448715

Payments from drug & device makers

$9,455in general payments, 2019–2025

Across 197 payments — averaging $48.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Boston Scientific$1K
  • Apollo Endosurgery US Inc$665
  • Johnson & Johnson$532
  • Phathom Pharmaceuticals, Inc.$519
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$8,96395%
  • Education$4925%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,455 in reported general payments places this provider in the 75th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$21,069
Medicare patients
78
Services billed
151

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbsrelaTenapanor Hcl24$39,980
OzempicSemaglutide22$19,751
MounjaroTirzepatide15$17,320
TrulancePlecanatide29$16,294
LinzessLinaclotide12$8,253
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C47$6,272
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates34$2,113
Omeprazole115$978
Sucralfate60$978
CholestyramineCholestyramine (With Sugar)16$762
Pantoprazole Sodium104$666
Famotidine31$217
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl17$215
Dicyclomine Hcl13$131
Lactulose11$127

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ardelyx, Inc.Ibsrela$55$39,98024 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance, Plenvu$1,511$22,56676 claims
Lilly USA, LLCMounjaro$65$17,32015 claims
AbbVieLinzess$2,640$8,25312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →